MDT-AP-1327
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 6
- sex
- M
- new_clusters
- C6
- umap1_2d
- 4.733805827
- umap2_2d
- 5.795970098
- umap1_3d
- 2.901072901
- umap2_3d
- -1.169923727
- umap3_3d
- -4.050899645
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.230
- KRAS_SIGNALING_DN+0.170
- INTERFERON_ALPHA_RESPONSE+0.130
- SPERMATOGENESIS+0.110
- INTERFERON_GAMMA_RESPONSE+0.090
- PANCREAS_BETA_CELLS+0.050
- COAGULATION-0.010
- IL6_JAK_STAT3_SIGNALING-0.030
- APICAL_SURFACE-0.040
- XENOBIOTIC_METABOLISM-0.040
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- MTORC1_SIGNALING-0.480
- UV_RESPONSE_DN-0.470
- MYC_TARGETS_V1-0.460
- TGF_BETA_SIGNALING-0.460
- MYC_TARGETS_V2-0.440
- TNFA_SIGNALING_VIA_NFKB-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.440
- HYPOXIA-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8942987 | — | — | 0.920 |
| 2 | SRR934844 | — | — | 0.919 |
| 3 | SRR8942981 | — | — | 0.916 |
| 4 | SRR25617833 | — | B | 0.915 |
| 5 | MNG499 | — | — | 0.910 |
| 6 | TCGA-49-AARQ-01A-11R-A41B-07 | — | cohortA1 | 0.909 |
| 7 | SRR10900593 | — | — | 0.903 |
| 8 | SRR33346946 | — | — | 0.902 |
| 9 | SRR598533 | GTEX | — | 0.902 |
| 10 | AUR-AD9G-TTP1-B-4-0-R-A584-39 | — | D | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.090 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |